The reduction in serum APOA1 levels was used as an independent predictor for metastasis or unfavorable prognosis of many cancers, such as ovarian cancer,6 nonsmall cell lung carcinoma (NSCLC),7 nasopharyngeal carcinoma (NPC),8 colorectal cancer,9 lymphoma,10 prostate cancer, 11 and renal cell cancer (RCC).12 On the other hand, increased expression of APOA1 was seen in some other types of cancers including small cell lung carcinoma (SCLC), hepatocellular carcinoma (HCC) and bladder cancer. Here, APOA1 is linked to urinary bladder carcinoma.